Rollover GlaxoSmithKline TESARO-sponsored niraparib study

People with Ovarian Cancer are asked to participate in a research study being conducted by Monter Cancer Center.

You may be eligible to participate in this study if you:
• Understand the study procedures and agrees to participate in the study by providing written informed consent.
• Are currently receiving treatment with niraparib
• Are currently benefiting from treatment with niraparib as assessed by the Investigator

You may NOT participate in this study if you:
• Have been permanently discontinued from niraparib treatment in the parent study for any reason.
• Currently have unresolved toxicities for which niraparib dosing has been interrupted in the parent study
• Are pregnant or breastfeeding

Contact Information
Mary Agnes Templeton, Study Coordinator
450 Lakeville Road
Lake Success, New York 11042
Phone: (516) 734-8979
Fax: (516) 734-8909
Email: MTEMPLETON@NORTHWELL.EDU

Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Women with Ovarian Cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age
  • Have a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer
  • Have platinum-resistant disease
  • Have completed any major surgery at least 4 weeks prior to first dose of

MIRV and have recovered or stabilized from the side effects of prior surgery

  • Have adequate hematologic, liver and kidney functions

You may NOT participate in this study if you:

  • Have primary platinum-refractory disease
  • Have folate deficiency (take folate supplements)
  • Have active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring
  • Have a serious concurrent illness or clinically relevant active infection
  • Have a clinically significant cardiac disease
  • Have a history of hemorrhagic or ischemic stroke or a history of cirrhotic liver disease
  • Are pregnant or breastfeeding

Contact Information
Martina Kracikova, Study Coordinator
One Gustave L. Levy Place, Box 1170 New York, NY 10029
Phone: (212)-824-7859
Fax: (212) 824 2347
Email: martina.kracikova@mssm.edu

Ovarian Cancer (OVATION 2)

People with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer are asked to participate in a research study being conducted by Northwell Health.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age or older
  • Have histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

You may not participate in this study if you:

  • Have received prior chemotherapy for any abdominal or pelvic tumor
  • Are receiving treatment for active autoimmune disease such as systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis
  • Have known hepatitis
  • Are pregnant or breastfeeding

Contact Information

Sarah Davis, Study Coordinator
Monter Cancer Center
450 Lakeville Road
Lake Success, New York 11042
Phone: (516) 734-7632
Email: sdavis22@northwell.edu

19-11-175 / TX226752

 

Platinum-Resistant Ovarian Cancer

A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)

Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age or older
  • Have histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

You may not participate in this study if you:

  • Have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
  • Have had gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition
  • Have known past or current coagulation defects leading to an increased risk of bleeding
  • Have clinically significant cardiac disease
  • Have active ocular surface disease
  • Have ongoing, acute, or chronic inflammatory skin disease
  • Have uncontrolled tumor-related pain
  • Have Inflammatory lung disease requiring chronic medical therapy
  • Have Grade 3 or higher pulmonary disease unrelated to underlying malignancy
  • Have Grade >1 peripheral neuropathy
  • Have inflammatory bowel disease including Crohn’s disease and ulcerative colitis
  • Are pregnant, breastfeeding or plan to become pregnant

Contact Information
Martina Kracikova, PhD, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, New York 10029
Phone: 212 824 7859
Email: martina.kracikova@mssm.edu